Core Viewpoint - The stock price of Yidu Tech (02158) surged over 9% after the approval of a key laboratory focused on intelligent diagnosis and treatment systems, marking a significant milestone in the company's specialization in intelligent diagnosis [1] Company Summary - Yidu Tech's stock rose by 7.45% to HKD 6.35, with a trading volume of HKD 149 million [1] - The company is a core partner in the newly approved "Multimodal Intelligent Diagnosis and Treatment System Research and Application Key Laboratory" led by Peking University First Hospital, focusing on intelligent diagnosis for metabolic syndrome [1] - Yidu Tech will integrate its large model technology capabilities into the laboratory's research chain, providing a solid foundation for the implementation of intelligent diagnosis [1] Industry Summary - The global AI healthcare market is entering a trillion-dollar growth phase, with an estimated market size of USD 26.65 billion (approximately RMB 186.1 billion) in 2024, projected to soar to USD 505.59 billion (approximately RMB 3.5 trillion) by 2033, reflecting a compound annual growth rate of 38.8% [1] - Dongguan Securities indicates that the active involvement of domestic tech giants in the AI healthcare sector is expected to accelerate the informatization and accessibility of healthcare in China, making healthcare a significant breakthrough area for AI applications [1]

Group 1 - The Hong Kong stock market saw a significant rise in AI application stocks, with notable increases in share prices for several companies [1] - Zhihui (智谱) surged by 19% to reach a new high since its listing, with a latest price of 188.800 and a total market capitalization of 831.15 billion [2] - Weimeng Group (微盟集团) increased by over 16%, with a latest price of 2.340 and a market cap of 92.67 billion [2] Group 2 - Mai Fushi (迈富时) rose by more than 13%, with a latest price of 43.920 and a market capitalization of 112.48 billion [2] - MINIMAX-WP (MINIMAX-WP) experienced an 11.88% increase, reaching a price of 386.000 and a total market value of 1193.73 billion [2] - Fourth Paradigm (第四范式) saw a growth of over 10%, with a latest price of 54.800 and a market cap of 284.51 billion [2] Group 3 - Yidu Technology (医渡科技) increased by 8.46%, with a latest price of 6.410 and a market capitalization of 67.99 billion [2] - Kingdee International (金蝶国际) rose by 7.88%, reaching a price of 15.610 and a total market value of 554.07 billion [2] - 汇量科技 (汇量科技) saw a 7.09% increase, with a latest price of 18.720 and a market cap of 294.68 billion [2] Group 4 - Meitu (美图公司) increased by 6.94%, with a latest price of 8.480 and a market capitalization of 388.91 billion [2] - Inspur Digital (浪潮数字企业) rose by 5.94%, reaching a price of 5.710 and a market cap of 69.75 billion [2] - 微创机器人-B (微创机器人-B) saw a 6.25% increase, with a latest price of 26.840 and a market cap of 276.81 billion [2]

Group 1 - The core viewpoint of the article highlights the strong stock performance of Yidu Tech (02158), which saw a price increase of over 9% after the opening, closing at 6.35 HKD with a trading volume of 149 million HKD [1] - Yidu Tech participated in the establishment of a key laboratory focused on the development and application of a multimodal intelligent diagnosis and treatment system, led by Peking University First Hospital, marking a significant milestone in the company's commitment to specialized intelligent diagnosis [1] - The laboratory will concentrate on intelligent diagnosis for metabolic syndrome related to heart and kidney diseases, integrating Yidu Tech's large model technology capabilities into the research chain [1] Group 2 - The global AI healthcare market is entering a trillion-dollar growth phase, with a projected market size of approximately 26.65 billion USD (about 186.1 billion RMB) in 2024, expected to surge to around 505.59 billion USD (about 3.5 trillion RMB) by 2033, reflecting a compound annual growth rate of 38.8% [1] - Dongguan Securities indicates that the active involvement of domestic tech giants in the AI healthcare sector is likely to accelerate the informatization and accessibility of healthcare in China, positioning healthcare as a crucial breakthrough area for AI applications [1]

Core Viewpoint - Yidu Tech (02158) saw a significant stock increase of over 6%, currently trading at 5.94 HKD with a transaction volume of 74.37 million HKD, following the approval of a key laboratory focused on intelligent diagnosis and treatment systems for metabolic syndrome [1] Group 1 - The "Multimodal Intelligent Diagnosis and Treatment System Research and Application Key Laboratory" has been successfully approved, led by Peking University First Hospital with Yidu Tech as a core partner [1] - The laboratory will focus on intelligent diagnosis and treatment for heart-kidney metabolic syndrome, marking a significant milestone in Yidu Tech's commitment to specialized intelligent diagnosis [1] - Yidu Tech will integrate its large model technology capabilities into the laboratory's research chain, providing a solid foundation for the implementation of intelligent diagnosis [1] Group 2 - The development of medical artificial intelligence has entered a phase of value verification through practical application [1] - The establishment of the laboratory exemplifies a collaborative innovation model that integrates industry, academia, research, and medicine [1] - Yidu Tech has partnered with several renowned hospitals in China to establish joint laboratories, supporting research from data governance to model development and system construction [1]

Core Viewpoint - The recent approval of the "Multimodal Intelligent Diagnosis and Treatment System Research and Application Key Laboratory" led by Peking University First Hospital, with the participation of Yidu Tech (02158), marks a significant milestone in the company's focus on specialized intelligent diagnosis and treatment [1] Group 1: Company Developments - Yidu Tech's stock rose over 6% and was trading at 5.94 HKD with a transaction volume of 74.37 million HKD [1] - The laboratory will focus on intelligent diagnosis and treatment for metabolic syndrome related to heart and kidney diseases, showcasing Yidu Tech's commitment to advancing specialized healthcare solutions [1] - As a core co-builder of the laboratory, Yidu Tech will integrate its large model technology capabilities into the research chain, providing a solid foundation for the implementation of intelligent diagnosis [1] Group 2: Industry Trends - The development of medical artificial intelligence has entered a phase of value verification through practical applications, indicating a shift towards real-world implementation [1] - The establishment of the laboratory exemplifies a collaborative innovation model that integrates industry, academia, and healthcare, highlighting the importance of partnerships in advancing medical technology [1] - Yidu Tech has collaborated with several well-known hospitals in China to build joint laboratories, demonstrating its comprehensive technical capabilities from data governance to model development and system construction [1]

Core Insights - The core focus of the news is on the advancements and recognition of Yidu Technology in the AI healthcare sector, highlighting its participation in international collaborations and contributions to sustainable health development. Group 1: International Collaboration and Recognition - Yidu Technology has joined the Shanghai Cooperation Organization's Economic Platform Health Sustainable Development Working Committee, marking a significant step in international health cooperation [1][6] - CEO Xu Jiming has been elected as the first director of the committee, reflecting the company's technical strength and contributions to the industry [6] - Yidu Technology was appointed as a vice-chair unit of the China Internet Association's Smart Healthcare Working Committee, aiming to promote the development of smart healthcare [9] Group 2: Academic and Research Initiatives - Founder and Chairman Gong Rujing has been appointed as a member of the Advisory Committee of the Hong Kong City University Digital Medicine Research Institute, recognizing her efforts in integrating AI and big data in healthcare [2] - Yidu Technology has established a practice base with Tsinghua University's School of Public Health, resulting in 11 research outputs and advancements in key technologies [17] Group 3: Innovation and Industry Development - At the 2025 China Social Medical New Ecology Conference, CEO Xu Jiming emphasized the need for non-public healthcare to transition from resource competition to value and experience competition, proposing three key areas for enhancing core competitiveness [15] - Yidu Technology shared its experiences in AI-driven clinical trials at the AI + Drug Development Salon, focusing on improving clinical trial efficiency and data quality [16] - The company participated in the China and International Development Forum, discussing innovative digital health cooperation models [11]

Core Viewpoint - The Hong Kong stock market has shown significant strength in early 2026, particularly in the AI healthcare sector, with companies like Yidu Tech experiencing notable stock price increases due to positive market expectations and supportive policies [1][2]. Group 1: Company Performance - Yidu Tech achieved a three-day stock price increase from January 2 to January 6, 2026, with a closing price of 5.66 HKD on January 6, reflecting a cumulative rise of over 8% [1]. - The company has been recognized as one of the first partners in the Henan Province National Artificial Intelligence Application Pilot Base (medical field), further solidifying its core advantages in AI healthcare technology [1]. Group 2: Industry Trends - The AI healthcare sector is experiencing strong overall performance driven by favorable policies, including two recent initiatives from Beijing aimed at promoting AI applications in healthcare from 2026 to 2027 [1]. - The "Action Plan" released by Beijing outlines a vision for widespread application of AI technology across the entire healthcare process by 2027, enhancing the quality of medical services for the public [1]. - Institutions are optimistic about the growth potential of the AI healthcare industry, anticipating that the synergy between policy support and clinical demand will accelerate the implementation of AI healthcare technologies [2].

Summary of Key Points from the Conference Call Industry Overview - **Industry**: China Healthcare - **Outlook**: The healthcare industry is expected to experience growth driven by supportive policies, innovation, and the expansion of commercial insurance, which will create a sustainable growth environment starting in 2026 [1][2][10]. Core Insights and Arguments 1. **Speculative Rally and Fundamentals**: The rally in the first half of 2025 was driven by speculators, but long-term investors are returning due to improved fundamentals in the second half of 2025 [1]. 2. **Commercial Insurance Expansion**: The commercial health insurance market is projected to expand significantly, potentially covering 30% of national direct medical expenditures, which could lead to a 3-5x growth in the domestic innovative drug market [2][9][10]. 3. **Government Support for Biopharma**: The Chinese government is positioning biopharma as a strategic pillar industry, with initiatives like the National Venture Fund of Rmb100 billion to support innovative drug development [2][17]. 4. **Bio-manufacturing Growth**: China's bio-manufacturers are expected to strengthen their market position due to favorable US/China policies and increased clinical trial activities [3][54]. 5. **Medtech Expansion**: Medtech leaders are anticipated to grow through product upgrades and overseas market expansion, with companies like Mindray and MicroPort Scientific being key beneficiaries [4]. 6. **Impact of DRG Policies**: The worst impacts of Diagnosis-Related Group (DRG) policies are expected to be over, with hospitals likely to see revenue recovery starting in the second half of 2025 [6]. 7. **AI Integration in Healthcare**: Larger hospitals are budgeting significant amounts for AI technologies, which is expected to benefit online healthcare platforms [5]. Additional Important Insights 1. **Clinical Trial Growth**: There has been a notable increase in clinical trial numbers in China, particularly for innovative drugs, which is expected to continue into 2026 [59][60]. 2. **Prescription Trends**: A significant shift is occurring in prescription patterns, with generics dominating public prescriptions and online platforms benefiting from prescription outflow [65][70]. 3. **Investment in Innovative Drugs**: The financing for innovative drugs in China has seen a substantial increase, with total financing reaching Rmb102.6 billion in 2025, marking a 38% increase [43]. 4. **Geopolitical Considerations**: There are minimal concerns regarding the geopolitical landscape affecting the biotech sector, although the upcoming announcement of the 1260H list may cause short-term volatility [64]. Top Investment Picks - **Pharma/Biotech**: Hengrui, Ascletis, Abbisco, Wuxi Apptec, Tigermed, Hygeia, SSY, AliHealth, Yidu Tech [2][3][4][5][6][10]. - **Medtech**: Mindray, United Imaging, MicroPort Scientific [4]. This summary encapsulates the key points discussed in the conference call, highlighting the growth potential and strategic shifts within the China healthcare industry.

呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 2,500,000,000 | | USD | | 0.00002 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有 ...

Core Viewpoint - The article highlights the successful application of Alibaba's AI model for early detection of pancreatic cancer, showcasing its potential to save lives by identifying tumors that may be missed by traditional methods [1][4][17]. Group 1: AI Model and Its Impact - The AI model, named DAMO PANDA, has analyzed over 180,000 CT scans, leading to the detection of 24 cases of pancreatic cancer, with 14 being in early stages [17]. - The model demonstrated a 93% accuracy rate in identifying pancreatic lesions from non-contrast CT scans, which are commonly used in routine checks [10][17]. - The cost of the screening using the AI model is approximately $25, making it accessible for many patients [15]. Group 2: Clinical Implementation and Results - The AI tool was tested at the Affiliated People's Hospital of Ningbo University, where it flagged cases that had previously shown no alarms, leading to timely interventions [6][10]. - Dr. Zhu Kelei, a key figure in the implementation, stated that the AI has unequivocally saved lives by detecting cancers that would have otherwise gone unnoticed [10][17]. - The model has issued alerts for about 1,400 scans, with around 300 requiring follow-up, indicating its effectiveness in clinical settings [11]. Group 3: Broader AI Healthcare Landscape - The article notes that Alibaba's AI technology is being promoted globally, covering nine countries and serving 20 million people, indicating a significant expansion of its application [18]. - Other major Chinese tech companies are also investing in AI healthcare, with initiatives from Ant Group, Huawei, and JD.com, reflecting a competitive landscape in AI medical applications [19]. - The Chinese AI healthcare market is projected to grow significantly, with estimates suggesting a rise from 8.8 billion yuan in 2023 to 315.7 billion yuan by 2033, indicating a compound annual growth rate of 43.1% [26].